CU24704B1 - Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso - Google Patents
Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nerviosoInfo
- Publication number
- CU24704B1 CU24704B1 CU2019000077A CU20190077A CU24704B1 CU 24704 B1 CU24704 B1 CU 24704B1 CU 2019000077 A CU2019000077 A CU 2019000077A CU 20190077 A CU20190077 A CU 20190077A CU 24704 B1 CU24704 B1 CU 24704B1
- Authority
- CU
- Cuba
- Prior art keywords
- alterations
- obtaining
- nervous system
- recombinant human
- human erythropoietin
- Prior art date
Links
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 title abstract 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 title abstract 2
- 230000004075 alteration Effects 0.000 title abstract 2
- 102000044890 human EPO Human genes 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 210000000653 nervous system Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 125000005629 sialic acid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se relaciona con las ramas de la Biotecnología y la Medicina y describe una composición farmacéutica de eritropoyetina humana recombinante con la microheterogeneidad de N-glicanos fucosilados formada por estructuras bi, tri y tetra-antenarias con residuos de ácidos siálicos mono y bi-sialilados que se encuentran en un rango del 40-60% del total de glicanos, los trisialilados entre un 40-43% y los tetrasialilados entre 10- 13%, este patrón de glicosilación le confiere propiedades que permiten su uso en alteraciones del sistema nervioso. Se describe además el método de obtención de la composición farmacéutica aquí descrita.</p>
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2019000077A CU24704B1 (es) | 2019-09-05 | 2019-09-05 | Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso |
| CA3150952A CA3150952A1 (en) | 2019-09-05 | 2020-02-19 | Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof |
| BR112022002954A BR112022002954A2 (pt) | 2019-09-05 | 2020-02-19 | Composição farmacêutica, método para obter uma rhepo, e, uso da composição farmacêutica |
| KR1020227009984A KR20220057553A (ko) | 2019-09-05 | 2020-02-19 | 인간 재조합 저시알릴화된 에리트로포이에틴, 그것의 정제 방법 및 치료 용도 |
| US17/640,133 US12569540B2 (en) | 2019-09-05 | 2020-02-19 | Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof |
| AU2020342140A AU2020342140B2 (en) | 2019-09-05 | 2020-02-19 | Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof |
| JP2022514643A JP2022546837A (ja) | 2019-09-05 | 2020-02-19 | ヒト組換えヒポシアル酸付加エリスロポエチン、その精製方法及び処置用途 |
| MX2022002765A MX2022002765A (es) | 2019-09-05 | 2020-02-19 | Eritropoyetina humana recombinante hiposialilada, metodos de purificacion y usos terapeuticos de esta. |
| EP20761739.0A EP4026555A1 (en) | 2019-09-05 | 2020-02-19 | Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof |
| CN202080062079.4A CN114340653B (zh) | 2019-09-05 | 2020-02-19 | 人重组低唾液酸化红细胞生成素、其纯化方法及治疗用途 |
| PCT/CU2020/050001 WO2021043345A1 (es) | 2019-09-05 | 2020-02-19 | Eritropoyetina humana recombinante hiposialilada, métodos de purificación y usos terapéuticos de esta |
| ARP200102407A AR119839A1 (es) | 2019-09-05 | 2020-08-26 | Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso |
| TW109129058A TWI864081B (zh) | 2019-09-05 | 2020-08-26 | 用於治療神經系統疾病的低唾液酸化之重組人紅血球生成素 |
| CONC2022/0002934A CO2022002934A2 (es) | 2019-09-05 | 2022-03-15 | Eritropoyetina humana recombinante hiposialilada, métodos de purificación y usos terapéuticos de esta |
| ZA2022/03661A ZA202203661B (en) | 2019-09-05 | 2022-03-30 | Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof |
| JP2024151043A JP2024164273A (ja) | 2019-09-05 | 2024-09-02 | ヒト組換えヒポシアル酸付加エリスロポエチン、その精製方法及び処置用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2019000077A CU24704B1 (es) | 2019-09-05 | 2019-09-05 | Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20190077A7 CU20190077A7 (es) | 2021-04-07 |
| CU24704B1 true CU24704B1 (es) | 2024-04-08 |
Family
ID=72242895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2019000077A CU24704B1 (es) | 2019-09-05 | 2019-09-05 | Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12569540B2 (es) |
| EP (1) | EP4026555A1 (es) |
| JP (2) | JP2022546837A (es) |
| KR (1) | KR20220057553A (es) |
| CN (1) | CN114340653B (es) |
| AR (1) | AR119839A1 (es) |
| AU (1) | AU2020342140B2 (es) |
| BR (1) | BR112022002954A2 (es) |
| CA (1) | CA3150952A1 (es) |
| CO (1) | CO2022002934A2 (es) |
| CU (1) | CU24704B1 (es) |
| MX (1) | MX2022002765A (es) |
| TW (1) | TWI864081B (es) |
| WO (1) | WO2021043345A1 (es) |
| ZA (1) | ZA202203661B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4612312A1 (en) * | 2022-11-02 | 2025-09-10 | F. Hoffmann-La Roche AG | Method for producing glycoprotein compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991005867A1 (en) * | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| NZ537306A (en) | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
| WO2005063808A1 (en) * | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| CN101090973B (zh) * | 2004-12-30 | 2012-03-28 | 克鲁塞尔荷兰公司 | 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质 |
| CU23317A1 (es) * | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
| CN101448852A (zh) * | 2005-12-20 | 2009-06-03 | 布里斯托尔—迈尔斯斯奎布公司 | 组合物和用于生产组合物的方法 |
| BRPI0711898A2 (pt) * | 2006-05-19 | 2011-12-27 | Glycofi Inc | composiÇço de proteÍna da eritropoietina substancialmente homogÊnea, composiÇço farmacÊutica, e, mÉtodos de aumentar hematàcrito em um mamÍfero, e de produzir uma composiÇço de eritropoietina |
| KR101847169B1 (ko) * | 2015-10-07 | 2018-04-09 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
| US11667686B2 (en) * | 2017-06-06 | 2023-06-06 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
-
2019
- 2019-09-05 CU CU2019000077A patent/CU24704B1/es unknown
-
2020
- 2020-02-19 EP EP20761739.0A patent/EP4026555A1/en active Pending
- 2020-02-19 MX MX2022002765A patent/MX2022002765A/es unknown
- 2020-02-19 CA CA3150952A patent/CA3150952A1/en active Pending
- 2020-02-19 KR KR1020227009984A patent/KR20220057553A/ko active Pending
- 2020-02-19 BR BR112022002954A patent/BR112022002954A2/pt unknown
- 2020-02-19 CN CN202080062079.4A patent/CN114340653B/zh active Active
- 2020-02-19 JP JP2022514643A patent/JP2022546837A/ja active Pending
- 2020-02-19 WO PCT/CU2020/050001 patent/WO2021043345A1/es not_active Ceased
- 2020-02-19 US US17/640,133 patent/US12569540B2/en active Active
- 2020-02-19 AU AU2020342140A patent/AU2020342140B2/en active Active
- 2020-08-26 AR ARP200102407A patent/AR119839A1/es unknown
- 2020-08-26 TW TW109129058A patent/TWI864081B/zh active
-
2022
- 2022-03-15 CO CONC2022/0002934A patent/CO2022002934A2/es unknown
- 2022-03-30 ZA ZA2022/03661A patent/ZA202203661B/en unknown
-
2024
- 2024-09-02 JP JP2024151043A patent/JP2024164273A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022002934A2 (es) | 2022-04-19 |
| MX2022002765A (es) | 2022-04-06 |
| US20220305084A1 (en) | 2022-09-29 |
| AR119839A1 (es) | 2022-01-12 |
| CU20190077A7 (es) | 2021-04-07 |
| KR20220057553A (ko) | 2022-05-09 |
| WO2021043345A1 (es) | 2021-03-11 |
| TW202114729A (zh) | 2021-04-16 |
| CN114340653B (zh) | 2023-01-31 |
| CN114340653A (zh) | 2022-04-12 |
| CA3150952A1 (en) | 2021-03-11 |
| EP4026555A1 (en) | 2022-07-13 |
| TWI864081B (zh) | 2024-12-01 |
| JP2022546837A (ja) | 2022-11-09 |
| JP2024164273A (ja) | 2024-11-26 |
| US12569540B2 (en) | 2026-03-10 |
| ZA202203661B (en) | 2023-09-27 |
| AU2020342140B2 (en) | 2024-05-02 |
| BR112022002954A2 (pt) | 2022-05-17 |
| AU2020342140A1 (en) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001430A1 (es) | Derivados de un inhibidor de fgfr. | |
| MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
| CR20180185A (es) | Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales | |
| CL2017002998A1 (es) | Plantas que tienen expresión modificada de thca sintasa | |
| CL2017001893A1 (es) | Uso de prg4 como agente antiinflamatorio | |
| AR095962A1 (es) | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos | |
| CO2022001097A2 (es) | Formulaciones anti-c5 de alta concentración | |
| CU20190073A7 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| SV2011003828A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| CL2019000787A1 (es) | Métodos para tratar trastornos mitocondriales y metabólicos. | |
| CL2015003346A1 (es) | Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas | |
| MX2019001327A (es) | Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido. | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| CL2018001548A1 (es) | Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas | |
| GT201200252A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| GT201700184A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| MX2022008065A (es) | 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. | |
| MX2017011510A (es) | Proteinas lisosomales glicosiladas, metodo de produccion y usos. | |
| MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| ITUA20162575A1 (it) | Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa | |
| MX2015016057A (es) | Solucion estabilizada de acido hipocloroso y uso de la misma. | |
| CU24704B1 (es) | Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso | |
| GT201700126A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos | |
| MX2022013398A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. |